PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. - Wikidata - awgldk - TriplyDB

PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases.

PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases.

http://www.wikidata.org/entity/Q36639023

about

The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies Protective effects and mechanisms of sirtuins in the nervous system Mechanisms and potential therapeutic applications of microglial activation after brain injury Perinatal asphyxia results in altered expression of the hippocampal acylethanolamide/endocannabinoid signaling system associated to memory impairments in postweaned rats.Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system Fenofibrate reduces mortality and precludes neurological deficits in survivors in murine model of Japanese encephalitis viral infection Peroxisome proliferator-activated receptor-α agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study Adult spinal cord radial glia display a unique progenitor phenotype Fasting Upregulates PPARalpha Target Genes in Brain and Influences Pituitary Hormone Expression in a PPARalpha Dependent Manner Is fenofibrate a reasonable treatment for diabetic microvascular disease?Effects of gemfibrozil on outcome after permanent middle cerebral artery occlusion in mice Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice.Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair.Multifaceted Mechanisms of WY-14643 to Stabilize the Blood-Brain Barrier in a Model of Traumatic Brain Injury Exploring uncoupling proteins and antioxidant mechanisms under acute cold exposure in brains of fish.The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice.Protective and antioxidant effects of PPARα in the ischemic retina.PPAR-alpha and PPAR-beta expression changes in the hippocampus of rats undergoing global cerebral ischemia/reperfusion due to PPAR-gamma status PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption Comparative gene expression analysis in mouse models for multiple sclerosis, Alzheimer's disease and stroke for identifying commonly regulated and disease-specific gene changes Characterization of fenofibrate-mediated anti-proliferative pro-apoptotic effects on high-grade gliomas and anti-invasive effects on glioma stem cells.Molecular Implications of the PPARs in the Diabetic Eye.PPARγ upregulation induced by vagus nerve stimulation exerts anti-inflammatory effect in cerebral ischemia/reperfusion rats Systemic medical management of diabetic retinopathy Therapeutic Effects of PPAR α on Neuronal Death and Microvascular Impairment.Broad-spectrum neuroprotection against traumatic brain injury by agonism of peroxisome proliferator-activated receptors Association of PPARα Intron 7 Polymorphism with Coronary Artery Disease: A Cross-Sectional Study MicroRNA involvement in mechanism of endogenous protection induced by fastigial nucleus stimulation based on deep sequencing and bioinformatics.New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury.PPARγ Is Activated during Congenital Cytomegalovirus Infection and Inhibits Neuronogenesis from Human Neural Stem Cells.Radiation-induced cognitive impairment--from bench to bedside Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland.The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects.Neurorestoration after traumatic brain injury through angiotensin II receptor blockage Sleep as a biological problem: an overview of frontiers in sleep research.KLF11 mediates PPARγ cerebrovascular protection in ischaemic stroke.The possible association between Toxoplasma gondii infection and risk of anxiety and cognitive disorders in BALB/c mice.Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.Natural products as promising drug candidates for the treatment of Alzheimer's disease: molecular mechanism aspect.

P2860

Q24646616-408A58FF-4F75-468A-96CC-85564676DAA8 Q26825585-55B5E866-9F42-4F7F-8ECC-D600039AF02A Q26864358-79491A89-0340-48A9-BB1B-D6F31FEED136 Q27322965-54AC5C53-F038-4A77-86F7-3981C510F6CB Q28389419-99AA2B52-5F4E-4B6A-BC65-F453716E398E Q28482311-1B6E1CCB-53AE-44C2-9CB9-FFAA8C78DF7E Q28566540-2E0CED95-B14C-4ED1-A500-03D6644BA793 Q28661253-860E9288-D2B7-4FD8-A587-6C853ED45756 Q28740471-1879BA9D-C6F8-4803-8C30-986D028DA831 Q30318829-4483D3DE-42BE-4FF7-A2F2-FA10270A1A5D Q30372692-AB2EADFE-6961-4166-813C-A173340B8593 Q33442332-2DDE431B-0A1F-48BB-ABC4-A9F9561C3232 Q33499205-BA6503F9-0C6D-435F-93B0-9EBF07861316 Q33610240-E2B135C7-71C7-48EC-8933-D3A96C3434F4 Q33729415-0CA16A96-C698-4817-9713-5996FDB25941 Q33862628-15D4D5E2-9154-4F31-B485-5E0759CA0771 Q33919749-8EBEFD34-BD3B-4566-8B9D-4663AFC1CEB9 Q33943655-7E5522A7-0508-4B77-93F6-812E4D0246D1 Q34203838-C32F220B-3D41-47F5-A771-27221A5ADF65 Q34302561-FF60242D-0967-4FD2-94DE-94CC45602525 Q34381637-F2A96AC1-9BB4-4E03-A35E-69A1107AEA2E Q34402079-3B7DBA88-E849-4D2E-B7D4-1131DECA424E Q34594935-FC6F8DD3-27B0-46A5-BD68-D08A24E6C0A6 Q35027487-D30BA344-F99D-4264-A546-2E7E39DD3ACF Q35067111-EB28CF9C-0E5C-4E96-9365-C308B1EE880E Q35078274-0CC37030-50E7-42D5-AD6E-F64F7C573B71 Q35603688-A8A4694D-9293-4025-9BFF-CDA47F4BE55D Q35684245-84242FA7-4E1C-4F6F-9993-1F2623AE6BE7 Q35849127-2E441003-AC40-4882-B91A-B66C39A27F04 Q35864188-5B68F4C5-DA78-4E8F-A2C1-A4C1ED61C490 Q35990083-0DA286BF-33A3-4AF6-985A-F61947E739C2 Q36344693-EA8C2AB8-5284-49EE-B5D6-6FA326AC4C56 Q36445100-0F90CA68-EE61-4EFD-8490-2F52EFD7B9B3 Q36445381-2AA76DF4-847A-4732-A18A-E4A52C4FA4BD Q36515931-D1A1AB20-943E-47EA-B2EE-A521E9DDD251 Q36547697-0B896EE1-5339-488D-9EEF-8C0870358C46 Q36732823-9524BF0F-8043-414E-8992-92E9F3F475D2 Q36733302-3219DCC4-8850-4BA6-B744-C1793DE1533A Q36992256-036F2487-E3FE-4FE9-8770-727DCCD066F8 Q37098664-76F4160F-3011-43B9-9A9D-C4585FAF24B7

P2860

PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases.

http://www.wikidata.org/entity/Q36639023

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

PPAR: a new pharmacological ta ...... nd neurodegenerative diseases.

@ast

PPAR: a new pharmacological ta ...... nd neurodegenerative diseases.

@en

type

label

PPAR: a new pharmacological ta ...... nd neurodegenerative diseases.

@ast

PPAR: a new pharmacological ta ...... nd neurodegenerative diseases.

@en

prefLabel

PPAR: a new pharmacological ta ...... nd neurodegenerative diseases.

@ast

PPAR: a new pharmacological ta ...... nd neurodegenerative diseases.

@en

P1433

Q36639023-73FF048B-FFF2-48CB-9935-57DF0B19477E

P1476

Q36639023-6F9EF8F3-78FD-48CF-B2F8-F7613A6F157D

P2093

Q36639023-1979044F-89DF-41E1-AEF1-9F08E5CC0BFA

Q36639023-2222284D-3CAD-49CA-BF98-6AB3D6535F92

Q36639023-36120A5C-5256-49AD-8731-891BAD8E137B

Q36639023-3EFF1D90-5FBF-4ACC-9833-9A6718A6EFC7

Q36639023-78FD39D6-4285-4998-BE08-7B23C270F4CF

Q36639023-9B65A711-366A-4891-AB19-984D2468DDAA

Q36639023-9E7C87C3-F183-4D49-A77C-6B8837B6F86B

Q36639023-CFE9A56B-C4BA-4EB8-8DA1-2F92FE2162D6

Q36639023-D863F6EA-13C2-4CB5-A9F6-AAE6D1E8CB96

Q36639023-DB1AAB26-CD21-487E-88A0-1FB490B33A44

P304

Q36639023-E87BB849-7DEE-4FD2-A5F8-C9DD06A2D2CF

P31

Q36639023-2A0F592D-2BD5-4D42-8300-002D81B60D3A

P356

Q36639023-A1FEC9EE-05ED-4846-82E5-FF06A46F4C7C

P433

Q36639023-318340CB-97C6-4596-A8AB-A2AEF362CF01

P478

Q36639023-7017FD4B-AE09-4927-ABF6-B02F087C3FC8

P50

Q36639023-D0D04AD7-7191-44B3-B933-607FF7BA7186

P577

Q36639023-24AB2579-15FF-459C-AE18-CC46A4D50454

P5875

Q36639023-4287BBA9-8F69-483D-85A9-4832A2E91DFD

P698

Q36639023-AA21B869-8543-4101-A438-0EDEA48BDEA6

P921

Q36639023-E9CA1E05-8001-4F96-A812-11F03D16CCBB

P356

P1433

Biochemical Society Transactions

P1476

PPAR: a new pharmacological ta ...... nd neurodegenerative diseases.

@en

P2093

Bastide M

http://www.w3.org/2001/XMLSchema#string

Bordet R

http://www.w3.org/2001/XMLSchema#string

Deplanque D

http://www.w3.org/2001/XMLSchema#string

Duriez P

http://www.w3.org/2001/XMLSchema#string

Fruchart JC

http://www.w3.org/2001/XMLSchema#string

Gautier S

http://www.w3.org/2001/XMLSchema#string

Gelé P

http://www.w3.org/2001/XMLSchema#string

Laprais M

http://www.w3.org/2001/XMLSchema#string

Ouk T

http://www.w3.org/2001/XMLSchema#string

Petrault O

http://www.w3.org/2001/XMLSchema#string

P304

1341-1346

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1042/BST0341341

http://www.w3.org/2001/XMLSchema#string

P433

Pt 6

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6722260

http://www.w3.org/2001/XMLSchema#string

P698

17073815

http://www.w3.org/2001/XMLSchema#string

P921

neurodegeneration